JP2020517611A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517611A5
JP2020517611A5 JP2019556610A JP2019556610A JP2020517611A5 JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5 JP 2019556610 A JP2019556610 A JP 2019556610A JP 2019556610 A JP2019556610 A JP 2019556610A JP 2020517611 A5 JP2020517611 A5 JP 2020517611A5
Authority
JP
Japan
Prior art keywords
mesylate salt
salt according
organic solvent
represented
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517611A (ja
JP7126514B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/004473 external-priority patent/WO2018194356A1/en
Publication of JP2020517611A publication Critical patent/JP2020517611A/ja
Publication of JP2020517611A5 publication Critical patent/JP2020517611A5/ja
Priority to JP2022129468A priority Critical patent/JP7390444B2/ja
Application granted granted Critical
Publication of JP7126514B2 publication Critical patent/JP7126514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556610A 2017-04-21 2018-04-18 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス Active JP7126514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022129468A JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
KR10-2017-0051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129468A Division JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Publications (3)

Publication Number Publication Date
JP2020517611A JP2020517611A (ja) 2020-06-18
JP2020517611A5 true JP2020517611A5 (https=) 2021-04-30
JP7126514B2 JP7126514B2 (ja) 2022-08-26

Family

ID=63857137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556610A Active JP7126514B2 (ja) 2017-04-21 2018-04-18 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
JP2022129468A Active JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022129468A Active JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Country Status (22)

Country Link
US (3) US11453656B2 (https=)
EP (1) EP3612529A4 (https=)
JP (2) JP7126514B2 (https=)
KR (3) KR102629654B1 (https=)
CN (1) CN110869367B (https=)
AR (1) AR111469A1 (https=)
AU (2) AU2018256227B2 (https=)
CA (1) CA3059543A1 (https=)
CO (1) CO2019011578A2 (https=)
EA (1) EA201992501A1 (https=)
IL (2) IL294666B2 (https=)
MA (1) MA49696A (https=)
MX (2) MX392634B (https=)
MY (1) MY201919A (https=)
NZ (1) NZ758443A (https=)
PH (1) PH12019502370A1 (https=)
SA (1) SA519410342B1 (https=)
SG (1) SG11201909615YA (https=)
TW (1) TWI776882B (https=)
UA (1) UA124364C2 (https=)
WO (1) WO2018194356A1 (https=)
ZA (1) ZA201907687B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SG11201913517UA (en) 2017-07-28 2020-02-27 Yuhan Corp Improved process for preparing aminopyrimidine derivatives
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク,インコーポレーテツド c-METエクソン14スキッピング変異を有する患者の治療
US12138351B2 (en) * 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100804566B1 (ko) 2003-12-25 2008-02-20 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법
DK1720853T3 (en) 2004-02-11 2016-03-29 Natco Pharma Ltd HIS UNKNOWN POLYMORPH FORM OF IMATINIBMYLYLATE AND PROCEDURE FOR PREPARING IT
NZ603525A (en) * 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2015003571A1 (zh) 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Similar Documents

Publication Publication Date Title
JP2020517611A5 (https=)
TWI640509B (zh) 製造喹啉化合物之方法及包含該化合物之醫藥組合物
TWI597277B (zh) 一種酪胺酸激酶抑制劑的二馬來酸鹽的第i型結晶及製備方法
JP6158811B2 (ja) 4−[5−(ピリジン−4−イル)−1h−1,2,4−トリアゾール−3−イル]ピリジン−2−カルボニトリルの結晶多形およびその製造方法
CN115461344B (zh) 一种glp-1受体激动剂的晶型a及其制备方法
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
JP2022517675A5 (https=)
CN110869367A (zh) 氨基吡啶衍生物化合物的盐、其结晶形式、以及用于制备它们的方法
JP2020033359A5 (https=)
TWI860993B (zh) 唑化合物晶體
WO2012155806A1 (zh) 4-氨基喹唑啉衍生物及其应用
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
JP2019504033A (ja) 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法
JP7314319B2 (ja) Cdk9阻害剤の結晶多形体及びその製造方法と用途
JP2023553021A (ja) ピロロピリミジン系化合物の塩、その結晶及びその使用
JP2025114691A (ja) オキサゾール化合物結晶
CN111989329A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
JP2024523506A5 (https=)
CN104628677A (zh) 一种沃替西汀有机酸盐晶型及其制备方法
CN101277694B (zh) 盐酸伊立替康的新晶形
CN104610195A (zh) 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
US20180111915A1 (en) Novel Polymorphic Form X of Nilotinib Dihydrochloride Hydrate
US20210380550A1 (en) New salt and solid state forms of escitalopram
JP2018509421A (ja) ニンテダニブジエタンスルホン酸塩結晶並びにその製造方法および使用